NovoLog (Insulin Aspart)
insulin aspart
Indications for Insulin Aspart
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Type 1 diabetes mellitus | Adults and pediatric patients ≥2 years | Mealtime (bolus) insulin in basal-bolus regimen or CSII pump therapy | FDA Approved |
| Type 2 diabetes mellitus | Adults | Mealtime insulin adjunctive to basal insulin and/or oral antidiabetic agents | FDA Approved |
Insulin aspart received initial FDA approval in June 2000 as a rapid-acting human insulin analog for glycemic control in diabetes. It is produced via recombinant DNA technology in Escherichia coli and differs from human insulin by a single amino acid substitution — proline replaced by aspartic acid at position B28. This substitution weakens hexamer stability, enabling faster dissociation into monomers at the injection site and consequently faster absorption than regular human insulin. In type 1 diabetes, insulin aspart serves as the mealtime bolus component of a basal-bolus regimen or via CSII pump therapy. In type 2 diabetes, it addresses postprandial glucose excursions when basal insulin alone is insufficient. It may also be administered intravenously under medical supervision. Pediatric use is supported by clinical studies in children aged 2–17 years with type 1 diabetes (FDA PI).
Diabetic ketoacidosis (DKA): Subcutaneous rapid-acting insulin analogs including insulin aspart have been studied as alternatives to IV regular insulin in mild-to-moderate DKA. Evidence quality: Moderate (Cochrane review).
Gestational diabetes mellitus: Insulin aspart is used off-label when mealtime insulin is needed during pregnancy. Animal studies showed no adverse developmental effects at clinically relevant doses, and limited human data support its use. Evidence quality: Moderate.
Hyperkalemia (IV): Used with dextrose to drive potassium intracellularly. Evidence quality: Low (insulin class effect).
Dosing of Insulin Aspart
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| T1DM — basal-bolus, mealtime coverage | 50–70% of total daily dose divided across meals | Individualized by ICR and correction factor | No fixed ceiling | Total daily insulin: typically 0.5–1.0 units/kg/day Inject 5–10 min before meal; remainder as basal insulin |
| T1DM — insulin pump (CSII) | ~50% as basal rate; boluses per meal via ICR | Programmed basal rates + meal boluses | No fixed ceiling | Change infusion set per manufacturer instructions; reservoir at least every 7 days Do NOT dilute or mix with other insulins in pump; do NOT exceed 98.6°F (37°C) |
| T2DM — adding mealtime insulin to basal | 4 units or 10% of basal dose once daily at largest meal | Titrate by 1–2 units twice weekly to postprandial target | No fixed ceiling | Advance to additional meals as needed (basal-plus to basal-bolus) If HbA1c <8%, consider reducing basal by 4 units or 10% when adding bolus |
| T2DM — full basal-bolus intensification | Divide mealtime insulin across 3 meals | Titrate per pre-meal and 2-h postprandial glucose | No fixed ceiling | Total daily dose often 0.5–1.2 units/kg/day May require more basal insulin than with regular human insulin to prevent pre-meal hyperglycemia |
| IV insulin infusion (hospital) | Dilute to 0.05–1.0 unit/mL in 0.9% NaCl | Per institutional protocol | Protocol-dependent | Under medical supervision; monitor glucose and potassium closely Also stable in other infusion fluids per FDA PI |
Pediatric Dosing (≥2 Years, Type 1 Diabetes)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| T1DM — mealtime coverage (SC or pump) | Individualized; total daily 0.5–1 unit/kg/day typical | By ICR and correction factor | No fixed ceiling | Inject 5–10 min before meal PK/PD differences vs regular insulin similar in children (6–12 yr) and adolescents (13–17 yr) as in adults |
NovoLog (insulin aspart) is administered 5–10 minutes before a meal, compared with 15 minutes for Humalog (insulin lispro). Both reach peak concentration approximately twice as fast as regular human insulin (NovoLog Tmax 40–50 min vs regular insulin 80–120 min). In clinical trials, insulin aspart demonstrated greater Cmax (82 mU/L vs 36 mU/L at 0.15 U/kg) and significantly less intra-individual variability in time to peak than regular human insulin, which may translate to more predictable postprandial glucose control (FDA PI). The FDA PI also notes that some patients may require more basal insulin when switching from regular human insulin to insulin aspart due to aspart’s shorter duration of action.
Pharmacology of Insulin Aspart
Mechanism of Action
Insulin aspart is a recombinant human insulin analog produced in Escherichia coli via rDNA technology. It is homologous with human insulin except for a single substitution of proline by aspartic acid at position B28 on the insulin B-chain. This substitution introduces a negative charge that weakens the hydrophobic interactions responsible for hexamer self-association, resulting in faster dissociation into dimers and monomers at the subcutaneous injection site. The accelerated monomer availability drives rapid absorption into the bloodstream. Once circulating, insulin aspart binds to the insulin receptor with affinity comparable to endogenous human insulin, activating intracellular signaling through the PI3K/Akt pathway. This promotes glucose transporter (GLUT4) translocation to the cell surface in skeletal muscle and adipose tissue, stimulates glycogen synthesis, suppresses hepatic glucose production, and inhibits lipolysis and proteolysis. The result is effective control of postprandial glucose excursions with a shorter action window than regular human insulin.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Onset ~15–20 min; Tmax 40–50 min (median); Cmax ~82 mU/L at 0.15 U/kg (vs 36 mU/L regular insulin); bioavailability similar to regular human insulin; absorption independent of injection site | Twice as fast Tmax as regular insulin with higher Cmax; less intra-individual variability in time to peak; administer 5–10 min before meal |
| Distribution | Protein binding <10% (low, similar to regular human insulin); clearance reduced 28% in BMI >32 kg/m² | Low protein binding means minimal displacement interactions; obese patients may have slower clearance but similar overall exposure |
| Metabolism | Degraded in liver, kidneys, and adipose tissue; identical pathway to endogenous human insulin | No CYP involvement; in renal impairment, insulin sensitivity increases — dose reduction may be needed. No clinically significant PK difference in hepatic impairment |
| Elimination | t½ ~81 min (SC) vs 141 min for regular human insulin; clearance ~1.2 L/h/kg; duration 3–5 h | Faster elimination than regular insulin reduces late postprandial hypoglycemia; shorter duration means patients may need more basal insulin when switching from regular insulin |
Side Effects of Insulin Aspart
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hypoglycemia (any severity) | Most common adverse reaction overall | Rates depend on dose, glycemic targets, concomitant medications, and diabetes type. Severe hypoglycemia rates (24 wk): T1DM adults 17%, T2DM adults 10%, T1DM pediatric 6% (FDA PI) |
| Headache | 12% | Reported in T1DM trials (NovoLog + NPH); comparable rate (10%) with regular human insulin |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Injection site reactions | 3–5% | Redness, swelling, itching at injection site; usually resolve within days to weeks; mitigated by site rotation |
| Weight gain | 1–5% | Anabolic effects of insulin and decreased glucosuria; common to all insulin therapy |
| Lipodystrophy | 1–2% | Lipohypertrophy or lipoatrophy at injection sites; alters insulin absorption; prevented by site rotation |
| Pruritus / Rash | 1–3% | May be localized or generalized; rates comparable to regular human insulin in clinical trials |
| Peripheral edema | ~5% | Insulin-mediated sodium retention; usually mild and self-limiting; may exacerbate heart failure with TZDs |
| Nausea | 7% | Reported in T1DM trials (NovoLog + NPH) vs 5% with regular insulin; usually transient |
| Diarrhea | 5% | Reported in T1DM trials; incidence higher than comparator (3%); usually self-limiting |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe hypoglycemia | T1DM adults 17%, T2DM adults 10%, T1DM pediatric 6% (24 wk) | 30 min–5 h post-injection (peak action window) | Oral glucose, glucagon, or IV dextrose; assess precipitating factors; adjust dose or timing |
| Anaphylaxis / severe allergic reaction | Rare | Minutes to hours after injection | Emergency treatment; permanent discontinuation of insulin aspart |
| Hypokalemia | Uncommon (dose-related) | Hours after large doses or with potassium-lowering drugs | Monitor potassium; supplement as needed; especially important with IV use |
| Heart failure exacerbation (with TZDs) | Uncommon | Weeks to months | Monitor for fluid retention; reduce or discontinue TZD if signs develop |
| Hyperglycemia/DKA from pump malfunction | Uncommon | Hours after pump failure | Switch to SC injection immediately; troubleshoot pump; monitor ketones |
| Localized cutaneous amyloidosis | Rare (post-marketing) | Months to years with repeated injections at same site | Change injection site; do not inject into affected areas; erratic absorption may result |
The risk of hypoglycemia is highest during the first 1–5 hours after injection of insulin aspart, coinciding with its peak glucose-lowering action. Because insulin aspart has a shorter duration than regular human insulin, late postprandial hypoglycemia (3–6 hours post-meal) is less common. However, the FDA PI notes that some patients switching from regular human insulin to insulin aspart may require more basal insulin and potentially more total insulin to prevent pre-meal hyperglycemia. Key risk factors for mealtime hypoglycemia include skipping or delaying meals after injection, unplanned exercise, and alcohol. Patients should carry fast-acting glucose at all times.
Drug Interactions with Insulin Aspart
Insulin aspart is degraded proteolytically in the liver, kidneys, and adipose tissue with no CYP enzyme involvement. Drug interactions are pharmacodynamic, affecting glucose metabolism or masking hypoglycemia warning signs.
Monitoring for Insulin Aspart
-
Blood Glucose
Pre-meal, 2-h postprandial; per ADA targets
Routine Postprandial monitoring is essential for mealtime insulin titration. CGM recommended when available. ADA 2025 targets: pre-meal 80–130 mg/dL; 2-h postprandial <180 mg/dL. -
HbA1c
Every 3 months until stable, then every 6 months
Routine In pivotal trials, HbA1c changes were comparable between insulin aspart and regular human insulin. -
Potassium
With IV use; periodically with SC in at-risk patients
Trigger-based All insulins drive potassium intracellularly. Especially important during IV infusion and in patients on potassium-lowering medications. -
Renal Function
Baseline, then per ADA guidelines
Routine Insulin sensitivity increases with declining renal function. Dose reduction may be needed. -
Injection / Infusion Sites
Every visit; pump sites per manufacturer
Routine Inspect for lipodystrophy and cutaneous amyloidosis. For pump users, change infusion set per manufacturer instructions. -
Pump Function
Continuous (for CSII users)
Routine Pump malfunction can cause rapid hyperglycemia and DKA since no subcutaneous depot persists. Patients must have backup SC injection supplies. -
Weight
Every visit
Routine Insulin therapy promotes weight gain. Track trends and reinforce lifestyle counseling.
Contraindications & Cautions for Insulin Aspart
Absolute Contraindications
- During episodes of hypoglycemia — do not administer while blood glucose is below normal range.
- Hypersensitivity to insulin aspart or any excipient (glycerin, phenol, metacresol, zinc, disodium hydrogen phosphate, sodium chloride) — anaphylaxis has been reported.
Relative Contraindications (Specialist Input Recommended)
- Significant heart failure (NYHA III–IV) with TZDs — combination increases fluid retention risk.
- Hypoglycemia unawareness — requires CGM and potentially relaxed glycemic targets.
Use with Caution
- Renal impairment — increased insulin sensitivity; dose reduction and closer monitoring needed.
- Hepatic impairment — no significant PK change observed, but gluconeogenic capacity may be diminished; monitor closely.
- Elderly patients (≥65 years) — conservative dosing recommended; HbA1c response did not differ by age in trials.
- Mixing insulins — NovoLog may be mixed with NPH insulin (draw aspart first); do NOT mix when using pump or IV.
Accidental mix-ups between insulin products have been reported. Patients must always verify the insulin label before each injection. Never share a NovoLog FlexPen, FlexTouch, PenFill device, syringe, or needle between patients, even if the needle is changed, due to the risk of transmitting blood-borne pathogens (FDA PI).
Patient Counselling for Insulin Aspart
Purpose of Therapy
Insulin aspart is a fast-acting mealtime insulin that controls the rise in blood sugar when you eat. It works alongside a longer-acting basal insulin or in an insulin pump to manage your blood sugar throughout the day. Unlike basal insulin, insulin aspart targets the blood sugar spike from each individual meal.
How to Take
Inject NovoLog 5 to 10 minutes before eating into the abdomen, thigh, upper arm, or buttocks. Rotate injection sites. For pump users, follow manufacturer instructions for infusion set changes. The solution should appear clear and colorless. Store unopened vials and pens in the refrigerator; once in use, store at room temperature (below 30°C / 86°F) for up to 28 days.
Sources
- Novo Nordisk. NovoLog (insulin aspart) injection, for subcutaneous or intravenous use. Full Prescribing Information. Plainsboro, NJ; Revised 2023. FDA Label (PDF) Primary regulatory reference for all dosing, indications, contraindications, adverse effects, and pharmacokinetic data.
- Novo Nordisk. NovoLog (insulin aspart) injection prescribing information. DailyMed/NLM. DailyMed Label NLM-hosted current labeling including patient information and instructions for use.
- Sanofi-Aventis. Merilog (insulin aspart-szjj) injection prescribing information. 2025. FDA Label (PDF) First insulin aspart biosimilar PI; approved February 2025 as biosimilar (not interchangeable) to NovoLog.
- Home PD, Lindholm A, Riis A, et al. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med. 2000;17(11):762-770. doi:10.1046/j.1464-5491.2000.00380.x Key pivotal trial in T1DM demonstrating comparable HbA1c with superior postprandial glucose control for insulin aspart vs regular human insulin.
- Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract. 2005;11(1):11-17. doi:10.4158/EP.11.1.11 Comparative trial informing the positioning of rapid-acting analogs within modern basal-bolus regimens.
- Garg SK, Rosenstock J, Ways K, et al. Efficacy and safety of insulin aspart biosimilar SAR341402 versus originator insulin aspart (GEMELLI 1). Diabetes Technol Ther. 2020;22(2):85-95. doi:10.1089/dia.2019.0382 Phase 3 trial supporting FDA approval of Merilog biosimilar, demonstrating non-inferiority in HbA1c and comparable safety profile.
- American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S181-S206. doi:10.2337/dc25-S009 Current ADA guidelines for mealtime insulin selection, carbohydrate counting, and insulin pump management.
- Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm—2023 Update. Endocr Pract. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001 AACE algorithm for stepwise intensification from basal to basal-bolus therapy with rapid-acting insulin analogs.
- Brange J, Ribel U, Hansen JF, et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature. 1988;333(6174):679-682. doi:10.1038/333679a0 Foundational protein engineering study demonstrating that B28 substitutions disrupt hexamer formation and accelerate insulin absorption.
- Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 Asp-insulin): absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22(9):1501-1506. doi:10.2337/diacare.22.9.1501 Key PK/PD study establishing the faster absorption, earlier peak, and shorter duration of insulin aspart compared with regular human insulin.
- Rubin R, Khanna NR, McIver LA. Aspart Insulin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Updated 2024 Jun 8. StatPearls Comprehensive review of insulin aspart pharmacokinetics including half-life (81 min), clearance (1.2 L/h/kg), and special population considerations.
- Heise T, Nosek L, Spitzer H, et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab. 2007;9(5):746-753. doi:10.1111/j.1463-1326.2007.00746.x Comparative PK study providing context for insulin aspart within the rapid-acting analog class alongside glulisine and lispro.
- Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, et al. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis. Cochrane Database Syst Rev. 2016;(1):CD011281. doi:10.1002/14651858.CD011281.pub2 Cochrane systematic review supporting subcutaneous rapid-acting insulin analogs (including aspart) for mild-to-moderate DKA in non-ICU settings.